开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

已收盘 12-19 16:08:47

0.990

-0.030

-2.94%

最高1.040	最低0.950	成交量33.25万
今开0.990	昨收1.020	日振幅8.82%
总市值4.43亿	流通市值4.43亿	总股本4.47亿
成交额33.34万	换手率0.07%	流通股本4.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":0.99,"timestamp":1734595727019,"preClose":1.02,"halted":0,"volume":332500,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.6521683,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.03,"latestTime":"12-19 16:08:47","open":0.99,"high":1.04,"low":0.95,"amount":333385,"amplitude":0.088235,"askPrice":1,"askSize":35000,"bidPrice":0.99,"bidSize":54500,"shortable":0,"etf":0,"ttmEps":-2.295330061056593,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1590076800000,"adjPreClose":1.02,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.712449,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2492457611","title":"华润三九增资至12.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2492457611","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492457611?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:47","pubTimestamp":1734598059,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["000999","BK1161","BK0028","BK1570","BK0188","BK0175","BK1515","BK1191","09939","BK0196","BK0060","BK0010","BK0183","03320","BK0239","BK0185","159938","BK1574","BK0012"],"gpt_icon":0},{"id":"2492145982","title":"泰德医药IPO：市场份额仅1%大客户依赖明显 核心子公司估值成谜是否涉及掏空上市公司资产？","url":"https://stock-news.laohu8.com/highlight/detail?id=2492145982","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492145982?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:32","pubTimestamp":1734597120,"startTime":"0","endTime":"0","summary":"　　近日，泰德医药（浙江）股份有限公司 Medtide Inc．向港交所递交招股书，拟香港主板挂牌上市，摩根士丹利、中信证券为其联席保荐人。这是继其于2024年5月31日递表失效后的再一次申请。　　泰德医药成立于2020年，公司主要向药企提供多肽新化学分子实体发现合成研发外包及多肽化学生产、制造及控制的研发生产外包服务。截至最后实际可行日期，泰德医药共有九个 GLP-1分子开发项目，开发口服或注射GLP-1分子产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-12-19/doc-inczysvv6880107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","09939","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2492145644","title":"减肥药企业银诺医药递表港交所：单品依赖明显 减重适应症或将直面司美格鲁肽仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2492145644","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492145644?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:26","pubTimestamp":1734596760,"startTime":"0","endTime":"0","summary":"　　近日，广州银诺医药集团股份有限公司向港交所主板提交上市申请，中信证券、中金公司为其联席保荐人。此前，公司曾于2022年12月与中信证券订立A股上市辅导协议，但最终并未提交A股上市申请。　　招股书显示，银诺医药成立于2014年，公司一直致力于研究及开发治疗糖尿病和其他代谢性疾病的创新疗法。目前，公司尚无商业化产品，在研管线方面，银诺医药已拥有多项针对糖尿病、肥胖、非酒精性脂肪性肝炎等适应症的研发管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-12-19/doc-inczysvr3958436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1515","BK1574","159938","09939"],"gpt_icon":0},{"id":"2492112663","title":"港股异动 | 同源康医药-B(02410)涨超7%创新高 海外重磅ADC获突破性疗法认定 公司核心产品正进行临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2492112663","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492112663?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:03","pubTimestamp":1734591834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超7%创上市新高，盘中高见50.5港元，较招股价12.1港元已涨超300%。截至发稿，涨6.28%，报49.95港元，成交额1174.21万港元。海通证券指出，Dato-DXd获首个突破性疗法认定，为EGFR突变NSCLC患者带来新希望。招股书显示，同源康医药公司已建立由11款候选药物组成的管线，包括2个低风险产品TY-9591、TY-302，5款创新临床产品，4款处于临床前阶段的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","BK1576","09939","BK4080","159938","BK1583","BK1161","ADC","BK4231","BK1141","BK1574","03347","BK1515"],"gpt_icon":0},{"id":"2492115400","title":"港股异动 | 亚盛医药-B(06855)午后涨超7% 耐立克和APG-2575展现突出疗效 机构看好公司未来营收高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2492115400","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492115400?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:39","pubTimestamp":1734586744,"startTime":"0","endTime":"0","summary":"消息面上，亚盛医药的耐立克与APG-2575 均在ASH大会上展现多项临床数据。同时，APG-2575在MM和MDS中均展现良好的初步疗效数据。展望未来，全球上市加速，核心产品有望于2026-2027年进入美国市场，预计在2024年APG-2575将递交NDA申请，并于2025年在中国获批上市，同时耐立克医保覆盖范围将进一步增加。此外，耐立克预计在2026年完成POLARIS-2临床试验并在美国提交NDA 申请，最快可于同年在美国上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","06855","APG"],"gpt_icon":0},{"id":"2492113984","title":"亚盛医药-B盘中异动 快速拉升5.21%报43.450港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492113984","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492113984?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:00","pubTimestamp":1734584431,"startTime":"0","endTime":"0","summary":"2024年12月19日下午盘13时00分，亚盛医药-B股票出现波动，股价大幅上涨5.21%。截至发稿，该股报43.450港元/股，成交量137.45万股，换手率0.44%，振幅9.08%。资金方面，该股资金流入2926.11万港元，流出1748.92万港元。亚盛医药-B股票所在的生物技术行业中，整体跌幅为0.82%。其相关个股中，永泰生物-B、思路迪医药股份、亚盛医药-B涨幅较大，振幅较大的相关个股有来凯医药-B、永泰生物-B、晶泰控股-P，振幅分别为18.50%、17.54%、13.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219130032a1fa48f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219130032a1fa48f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1515","06855","BK1574"],"gpt_icon":0},{"id":"2492919919","title":"港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492919919","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492919919?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:57","pubTimestamp":1734577079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","02898","01672","01477","02105","BK1515","BK1191","02257","09939","BK1574","159718"],"gpt_icon":0},{"id":"2492196120","title":"开拓药业-B盘中异动 早盘股价大跌5.88%报0.960港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492196120","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492196120?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:32","pubTimestamp":1734575533,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘10时32分，开拓药业-B股票出现波动，股价大幅下挫5.88%。截至发稿，该股报0.960港元/股，成交量1.6万股，换手率0.00%，振幅3.92%。资金方面，该股资金流入1980港元，流出1.343万港元。开拓药业-B股票所在的药品行业中，整体跌幅为0.27%。其相关个股中，励晶太平洋、草姬集团、中国医疗集团涨幅较大，振幅较大的相关个股有草姬集团、励晶太平洋、德琪医药-B，振幅分别为21.60%、10.61%、8.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219103213984cc46c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219103213984cc46c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2492167441","title":"佐力药业：12月16日接受机构调研，国联医药、平安基金参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2492167441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492167441?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:04","pubTimestamp":1734570257,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月18日佐力药业发布公告称公司于2024年12月16日接受机构调研，国联医药陈翠琼、平安基金刘杰 周思聪 黄文敏参与。佐力药业主营业务：药品的研发、生产和销售。该股最近90天内共有11家机构给出评级，买入评级9家，增持评级2家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900008195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","BK0042","300181","BK0239","BK0077","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2492900152","title":"这家企业专注“神药”研发！排名全球第三！相比同行增长却似乎差点意思！现要再冲IPO！","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900152","media":"IPO日报国际金...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492900152?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:46","pubTimestamp":1734522360,"startTime":"0","endTime":"0","summary":"从市场份额来说，泰德医药和这前两名龙头不能相比，占比较小。截至2024年6月30日，泰德医药的项目管线包括1046个进行中的CRO项目及332个进行中的CDMO项目。截至2024年11月28日，该公司与七名客户进行九个NCEGLP-1分子开发项目，开发口服及或注射GLP-1分子产品。相比上述同行企业的增长，泰德医药似乎还是稍逊一筹，甚至2023年还出现了营收和利润的下滑。目前来看，海内外市场“GLP-1”药物市场上下游均在解决扩产问题。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2024-12-18/doc-inczwuet7716816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2492777099","title":"盘点2024股票型基金业绩：申万菱信医药先锋A今年跌26.06%暂居跌幅榜首，安信医药健康A跌幅榜前20中规模最大","url":"https://stock-news.laohu8.com/highlight/detail?id=2492777099","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492777099?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:25","pubTimestamp":1734513900,"startTime":"0","endTime":"0","summary":"专题：2024基金行业年终大盘点：谁将夺冠？　　随着2024年即将接近尾声，资本市场再次证明了其不可预测性。　　从业绩跌幅来看，截止12月17日，申万菱信医药先锋A跌幅最大，今年以来回报为-26.06%，基金最新规模1.93亿元。　　值得一提的是，按申万菱信医药先锋A中报显示，截止今年6月30日，净利润已亏损1.84亿元，管理费却收了312万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-12-18/doc-inczwpwr4832404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1574","BK1515","BK1161","09939","150219"],"gpt_icon":0},{"id":"2492297620","title":"同源康医药-B盘中异动 临近收盘急速上涨6.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492297620","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492297620?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:58","pubTimestamp":1734508691,"startTime":"0","endTime":"0","summary":"2024年12月18日临近收盘15时58分，同源康医药-B股票出现波动，股价大幅拉升6.12%。截至发稿，该股报45.950港元/股，成交量16.45万股，换手率0.09%，振幅9.47%。同源康医药-B股票所在的生物技术行业中，整体涨幅为0.37%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。TY-2136b为自主研发、口服ROS1/NTRK抑制剂,用于治疗实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218155811ab813b36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218155811ab813b36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02410","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2492975505","title":"【券商聚焦】中信建投维持亚盛医药(06855)“买入”评级 指在重磅BIC潜力产品带动下未来营收有望保持高增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2492975505","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492975505?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:30","pubTimestamp":1734507031,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，亚盛医药 的耐立克与APG-2575均在ASH大会上展现多项临床数据。其中，耐立克在二线CP-CML患者中展现良好数据，74%的患者治疗后获CCyR，并且产品在Asciminib耐药后的患者中依旧展现37.5%的CCyR，疗效出色。该行指，公司已在血癌和实体瘤等领域搭建多个产品管线，在重磅BIC潜力产品的带动下未来营收有望持续保持高增长。该行预计亚盛医药2024-2026年将实现9.81、5.68、8.77亿元的收入，同比增长341.93%、-42.10%、54.45%，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949895","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","09939","159938"],"gpt_icon":0},{"id":"2492975443","title":"12月18日北大医药涨停分析：高校系，医药商业，新冠药物概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492975443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492975443?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:30","pubTimestamp":1734507010,"startTime":"0","endTime":"0","summary":"证券之星消息，北大医药12月18日涨停收盘，收盘价6.91元。该股于13点0分涨停，未打开涨停，截止收盘封单资金为3769.96万元，占其流通市值0.92%。12月18日的资金流向数据方面，主力资金净流入5063.78万元，占总成交额34.77%，游资资金净流出2016.4万元，占总成交额13.84%，散户资金净流出3047.38万元，占总成交额20.92%。近5日资金流向一览见下表：该股为高校系，医药商业，新冠药物概念热股，当日高校系概念上涨1.08%，医药商业概念上涨0.32%，新冠药物概念上涨0.01%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800021572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","000788","BK0096","159938","BK1574","BK0239","BK0028","BK0012","BK0060","BK0102","BK0122","09939"],"gpt_icon":0},{"id":"2492928938","title":"港股部分医药股走弱，来凯医药-B跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492928938","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492928938?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:30","pubTimestamp":1734492617,"startTime":"0","endTime":"0","summary":"南方财经12月18日电，港股部分医药股走弱，来凯医药-B跌超8%，为连续第五日下跌，刷新逾1个月低位；艾迪康控股、药师帮、科济药业-B等股跌幅居前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183271914271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","YANG","HSTECH","BK1515","BK1161","02105","HSCEI","09939"],"gpt_icon":0},{"id":"2492505947","title":"以全球创新为抓手迈向国际化纵深，亚盛医药(6855.HK)获“年度卓越大健康企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2492505947","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492505947?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:49","pubTimestamp":1734490161,"startTime":"0","endTime":"0","summary":"在日前第九届“格隆汇·全球投资嘉年华·2025”上揭晓的“金格奖”年度卓越公司评选中，亚盛医药(6855.HK)荣获“年度卓越大健康企业”奖项，受到市场关注。","market":"sg","thumbnail":"https://img7.gelonghui.com/column/10.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/10.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1495322","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06855","09939","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2492873944","title":"三诺生物：远信投资、中金医药等多家机构于12月17日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2492873944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492873944?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:04","pubTimestamp":1734487453,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月17日三诺生物发布公告称远信投资叶铮、中金医药张琎 朱言音 刘雅馨、德邦证券周新明 向潇、博时基金许炯东、诺安基金吕磊、腾讯健康朱叶、申万资管屈玲玉 李菁、宏道投资李永、Golden nest曾志文、中庚基金谢允昌、申万菱信姚宏福、创金合信皮劲松、Alpines capital张惠灵、国信资管隋欣于2024年12月17日调研我司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800012135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1515","BK1161","BK0114","BK0251","300298","BK1574","BK0102"],"gpt_icon":0},{"id":"2492941582","title":"创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2492941582","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492941582?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:55","pubTimestamp":1734486946,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念多数上扬，圣诺医药 涨11.56%，百奥赛图涨9.68%，歌礼制药涨7.98%，绿竹生物涨4.73%，再鼎医药涨4.41%，康诺亚涨1.34%，中国生物制药涨0.95%，信达生物涨0.69%银河证券表示，1）医药创新是医药增长的核心动力。对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949850","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","159992","01672","BK1587","BK1191","BK1588","01801","159938","BK1521","01177","09939","02315","BK1583","BK1515","06978","LU2488822045.USD","09688","02162","BK1161","LU2328871848.SGD","BK1574","BK1589","02257","02480"],"gpt_icon":0},{"id":"2492948414","title":"机构看好2025年医药核心资产估值修复 “创新”“出海”两大主线逻辑不改","url":"https://stock-news.laohu8.com/highlight/detail?id=2492948414","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492948414?lang=zh_cn&edition=full","pubTime":"2024-12-18 07:40","pubTimestamp":1734478800,"startTime":"0","endTime":"0","summary":"　　今年以来，医药板块表现低迷，申万医药生物行业指数在31个申万一级行业指数中涨幅垫底。展望2025年，多家券商研究机构认为医药板块具有估值修复空间，行业内上市公司盈利能力处于筑底阶段，龙头企业有望在行业见底回升后展现更强的竞争力。从投资主线看，“创新”和“出海”贯穿2024年，2025年这两大主线的逻辑仍将延续。　　中原证券研究指出，截至2024年12月1日，医药行业表现整体呈现“先抑后扬”走势。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-18/doc-inczvssv4167141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","BK1161","09939","159938"],"gpt_icon":0},{"id":"2492953179","title":"九州通(600998.SH)拟转让医药仓储物流基础设施公募REITs资产相关项目公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2492953179","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492953179?lang=zh_cn&edition=full","pubTime":"2024-12-17 19:51","pubTimestamp":1734436261,"startTime":"0","endTime":"0","summary":"九州首瑞持有基础设施公募REITs底层资产即武汉东西湖项目，截至2024年6月30日，武汉东西湖项目不动产评估值为10.98亿元，基础设施公募REITs拟募集资金金额11.11亿元。本次交易完成后，公司将不再持有九州首瑞股权，九州首瑞将不再纳入公司合并报表范围。同时，九州通物流或其同一控制下的相关方拟参与基础设施公募REITs份额的战略配售，认购占本次基金份额发售数量34%的份额，拟认购出资金额约为3.78亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0097","BK0187","BK0012","BK0250","BK0077","BK0183","BK0196","BK0188","600998","CFA","BK0039","BK0201","BK0146","09939","BK1515","159938","CFA.SI","BK1161","BK0028","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0467},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.0851},{"period":"6month","weight":-0.0727},{"period":"1year","weight":-0.3377},{"period":"ytd","weight":-0.3742}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商，专注于研究癌症药物及其他雄激素受体（AR）相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌（mCRPC）的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.058646},{"month":2,"riseRate":0.75,"avgChangeRate":0.213088},{"month":3,"riseRate":0.25,"avgChangeRate":0.062774},{"month":4,"riseRate":0.75,"avgChangeRate":0.545629},{"month":5,"riseRate":0.5,"avgChangeRate":0.006555},{"month":6,"riseRate":0.2,"avgChangeRate":-0.08997},{"month":7,"riseRate":0.6,"avgChangeRate":0.020249},{"month":8,"riseRate":0.2,"avgChangeRate":-0.059234},{"month":9,"riseRate":0.2,"avgChangeRate":-0.170155},{"month":10,"riseRate":0.2,"avgChangeRate":-0.081213},{"month":11,"riseRate":0.6,"avgChangeRate":0.071209},{"month":12,"riseRate":0.2,"avgChangeRate":-0.205944}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}